MedWatch

Demant closes Q2 ahead of guidance, upgrades both revenue and earnings

The Danish hearing aid supplier exits this year's second quarter beating prior guidance and now upgrades its full-year financial outlook – both for organic growth and operating earnings.

Demants presents its Q2 interim report Thursday morning. | Photo: Jens Dresling/Politiken/Ritzau Scanpix

Hearing aid company Demant's business has been booming in the first half of 2021 – so much so that the group now books an upward adjustment of its full-year guidance.

Demant now banks on organic growth of 26-30 percent against the prior spread of 24-28 percent, also dialing up on its expectations for annual earnings before interest and taxes from DKK 3-3.3bn (USD 470-520m) to DKK 3.15-3.45bn, the company informs in its H1 interim report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs